Bagsværd, Denmark, 24 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initi

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales THE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S foll

Novo Nordisk (NVO) may be bottoming as LLY share losses stabilize; trading ~15x forward earnings with catalysts like Wegovy pill & CagriSema.

Novo Nordisk A/S (NYSE:NVO) has entered a strategic partnership with Amazon Web Services to accelerate drug discovery and modernize its operations through artificial intelligence and cloud technology. The agreement establishes AWS as Novo Nordisk’s preferred cloud provider and strategic AI partner. The companies have also created a co-innovation hub in London, where AWS engineers and […]

Novo Nordisk stock trades calmly while a new late-stage Wegovy dose study and a proposed $245 Medica

Las acciones de Novo Nordisk mantienen su rango reciente mientras la compañía lanza una prueba de fase 3 de menor mantenimiento.

Las acciones de Novo Nordisk han bajado un 7,5% en 2026 incluso después de que su actualización del segundo trimestre de 2026 aumentara la orientación para todo el año y

Novo Nordisk (NVO) target price: $138.22 (199.5% upside). Current price: $46.16. See our analyst rating, optimistic/conservative scenarios, and 5-year forecast.